US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate at the 28th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Provides Corporate Update on Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Completion of Previously Announced Share Consolidation
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 8 Next >